Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 5Sarcoma 3Genitourinary 3Breast 3Other solid neoplasm 2Gastrointestinal 2Dermatologic 2CNS 2Tumor-Agnostic 1Other hematologic neoplasm 1Lymphoid 1Head & Neck 1

Conditions

Prostatic Neoplasms 1Neoplasm Metastasis 1Liposarcoma 1Gastrointestinal Stromal Tumors 1Colorectal Neoplasms 1Breast Neoplasms 1Adenocarcinoma of Lung 1

Interventions

Oxaliplatin 297Fluorouracil 272Bevacizumab 235Gemcitabine 234Leucovorin 212Capecitabine 204pembrolizumab 200Nivolumab 157Irinotecan 156Cisplatin 148Specimen Handling 143Magnetic Resonance Spectroscopy 130130-nm albumin-bound paclitaxel 115Paclitaxel 109durvalumab 104Cetuximab 102Radiotherapy 96atezolizumab 92Biopsy 92Drug Therapy 91Albumin-Bound Paclitaxel 78tislelizumab 77Taxes 73Folfox protocol 68lenvatinib 67Carboplatin 65regorafenib 60Blood Specimen Collection 60trifluridine tipiracil drug combination 52Ipilimumab 52

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Midazolam × Gastrointestinal × 1 year × Clear all
NCT05208047 2026-05-22

(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors

Cogent Biosciences, Inc.

Phase 3 Active not recruiting
482 enrolled
GastrointestinalSarcoma

Neoplasm Metastasis, Gastrointestinal Stromal Tumors

NCT04557449 2025-10-01

CDK4i

Pfizer

Phase 2 Active not recruiting
362 enrolled
BreastGastrointestinalGenitourinarySarcomaThoracic

Adenocarcinoma of Lung, Breast Neoplasms, Liposarcoma, Prostatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡